Generic Name and Formulations:
Naftifine HCl 1%; crm; gel.
Sebela Pharmaceuticals Inc.
Indications for NAFTIN:
Tinea pedis, t. cruris, t. corporis.
Crm: apply daily. Gel: apply twice daily. If no improvement within 4 wks, discontinue and reevaluate. Wash hands after application.
Discontinue if irritation occurs. Confirm diagnosis with KOH smear and/or culture. Avoid occlusive dressings, mucous membranes. Pregnancy (Cat.B). Nursing mothers.
Burning, stinging, dryness, erythema, itching, local irritation.
Crm, Gel—40g, 60g, 90g
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Once-Daily Oral Contraceptive for Men Shows Promise
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure